Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000905148-25-003013
Filing Date
2025-08-14
Accepted
2025-08-14 20:32:31
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 28664
2 ex998.htm EX-99.8 44888
  Complete submission text file 0000905148-25-003013.txt   75362
Mailing Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901
Business Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901 212-672-7050
VIKING GLOBAL INVESTORS LP (Filed by) CIK: 0001103804 (see all company filings)

EIN.: 134055118 | State of Incorp.: DE | Fiscal Year End: 1231

Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Subject) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91059 | Film No.: 251222044
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)